885500-46-9

Basic information

• Product Name: tert-butyl 4-(4-chlorophenyl)-4-formylpiperidine-1-carboxylate
• Synonyms: tert-butyl 4-(4-chlorophenyl)-4-formylpiperidine-1-carboxylate
• CAS NO: 885500-46-9
• Molecular Weight: 323.82
• Mol File: 885500-46-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(4-chlorophenyl)-4-formylpiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(4-chlorophenyl)-4-formylpiperidine-1-carboxylate(885500-46-9)
• EPA Substance Registry System: tert-butyl 4-(4-chlorophenyl)-4-formylpiperidine-1-carboxylate(885500-46-9)

Safety Data

• Hazardous Substances Data: 885500-46-9(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 672927-26-3 4-(4-chloro-phenyl)-4-hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester 
• 849106-01-0 4-(4-chloro-phenyl)-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-methyl ester 
• 644981-94-2 4-(4-chloro-phenyl)-piperidine-1,4-dicarboxylic acid mono-tert-butyl ester 
• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 
• 140-53-4 p-chlorobenzyl cyanide 
• 218451-34-4 4-(4-chloro-phenyl)-4-cyano-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 887129-22-8 tert-butyl-4-(4-chlorophenyl)-4-ethenylpiperidine-1-carboxylate 
• 672927-27-4 [4-(4-chloro-phenyl)-piperidin-4-yl]-methanol 
• 885500-47-0 4-(4-chloro-phenyl)-4-methylaminomethyl-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

ACYL SULFONAMIDE NAV1.7 INHIBITORS

The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (I)

TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.

PHARMACEUTICAL COMPOUNDS

The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof for use in the treatment or prophylaxis of a disease state or condition mediated by protein kinase A and/or protein kinase B, wherein the ring Q is a benzene ring; J2-J1 is N=CR7 or R1aN-CO; G is OH or NR5R6; E is CONR7, NR7CO, C(R8)=C(R8) or (X)m(CR8R8a)n where X is O, S or NR7; provided that when J2-J1 is R1aN-CO, E is other than NR7CO; m and n are each 0 or 1, where m + n = 1 or 2; A is a bond and R4 and R4a are absent, or A is a saturated optionally substituted C1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between E and G, one carbon atom in the linker group A being optionally replaced by O or N; R1,Rla, R2, and R3 are each H; halogen; C1-6 hydrocarbyl optionally substituted by halogen, OH or C1-2 alkoxy; CN; CONHR8; NH2; NHCOR10 or NHCONHR10; R4 is H or C1-4 alkyl; R4a is H, C1-4 alkyl or a group R9; R5 and R6 are each selected from H, R9 and C1-4 hydrocarbyl optionally substituted by halogen, C1-2 alkoxy or R9;or NR5R6 forms a saturated 4-7 membered monocyclic heterocyclic group; R7 is H or C1-4 alkyl; R8 and R8a each H or saturated C1-4 hydrocarbyl optionally substituted by fluorine; R9is a monocyclic or bicyclic carbocyclic or heterocyclic group containing up to 3 ring heteroatoms selected from N, O and S; or R4, R4a and A together form a saturated monocyclic 4-7 membered heterocycle; or NR5R6, R4 and A form a saturated 4-7 membered monocyclic heterocycle; or R4,together with R7 or R8 and A and E form a 4-7 membered saturated monocyclic heterocycle; or NR5R6 and R7 or R8 together with A and E form a 4-7 membered saturated monocyclic heterocycle; and R10 is optionally substituted phenyl or benzyl.